Zenflow was founded with the mission to provide a more effective and less invasive treatment for benign prostatic hyperplasia (BPH), a condition affecting millions of men worldwide. The company focuses on developing innovative medical devices designed to alleviate urinary obstruction caused by BPH, improving patients' quality of life without the need for traditional drugs or surgery. Zenflow aims to revolutionize the market for BPH treatments by offering a solution that addresses the limitations of current therapies.

Notable figures associated with Zenflow include experienced medical professionals and industry experts who contribute to its development and strategic direction. The company has attracted significant investment from leading venture capital firms, underscoring confidence in its potential. Key achievements include successful clinical trials demonstrating the efficacy and safety of their device. Zenflow's impact lies in its potential to transform BPH treatment, offering a non-invasive alternative that could benefit millions of men globally.